10-Q: Zimmer Biomet Q3 Sales Up, Acquisitions Drive Growth

Zimmer Biomet Holdings, Inc. reported a 9.7% increase in net sales for the third quarter of 2025, driven by strategic acquisitions and market growth, despite a decline in net earnings.

Summary

• Net sales for the three months ended September 30, 2025, increased by 9.7% to $2,001.4 million, compared to $1,824.2 million in the prior year period.
• Net sales for the nine months ended September 30, 2025, increased by 5.9% to $5,987.7 million, compared to $5,655.4 million in the prior year period.
• Net earnings for the three months ended September 30, 2025, decreased by 7.2% to $231.2 million, down from $249.2 million in the prior year period.
• Net earnings for the nine months ended September 30, 2025, decreased by 14.7% to $567.2 million, down from $665.1 million in the prior year period.
• Diluted earnings per common share were $1.16 for the three months and $2.84 for the nine months ended September 30, 2025, compared to $1.23 and $3.24, respectively, in the prior year periods.
• Operating profit increased by 25.7% to $351.3 million for the three months and by 5.2% to $943.6 million for the nine months ended September 30, 2025.
• The company completed the acquisition of Paragon 28, Inc. on April 21, 2025, for $1,241.5 million in initial cash consideration, plus potential contingent value rights (CVRs) up to $90.0 million.
• Subsequent to the quarter, on October 7, 2025, the company acquired Monogram Technologies Inc., an orthopedic robotics company, for approximately $180 million in initial cash consideration, plus potential CVRs up to $570 million.
• Cash and cash equivalents stood at $1,292.7 million as of September 30, 2025, a significant increase from $525.5 million at December 31, 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $1,179.7 million, up from $993.1 million in the prior year period.
• The company issued new senior unsecured debt securities totaling $2,492.1 million in proceeds during the nine months ended September 30, 2025, and redeemed $863.0 million of senior notes due 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive, reflecting strong top-line sales growth driven by strategic acquisitions and market expansion. However, this is tempered by a decline in net earnings and diluted EPS, increased interest expenses, and a higher tax rate, indicating that growth comes with significant costs and financial pressures. The long-term outlook is supported by restructuring benefits and strategic investments, but immediate profitability is challenged.

Positives

• Strong net sales growth of 9.7% for the three months and 5.9% for the nine months ended September 30, 2025, driven by strategic acquisitions, market growth, and new product introductions.
• Operating profit increased by 25.7% for the three months and 5.2% for the nine months, indicating improved operational efficiency before interest and taxes.
• Cost of products sold, excluding intangible asset amortization, decreased as a percentage of net sales in the three-month period (27.9% vs 29.5%), reflecting lower manufacturing costs and more efficient inventory use.
• Successful execution of restructuring programs is leading to ongoing savings, with the 2023 Restructuring Plan concluded and expected to reduce annual pre-tax operating expenses by $175 million to $200 million by the end of 2025.
• Significant increase in cash and cash equivalents to $1,292.7 million, bolstering liquidity.
• Net cash provided by operating activities increased to $1,179.7 million for the nine-month period, indicating strong operational cash generation.
• Strategic acquisitions of Paragon 28 (foot and ankle) and Monogram Technologies (orthopedic robotics) expand the company's portfolio into faster-growing and technologically advanced segments.
• New credit agreements (2025 Five-Year Revolving Facility of $1.5 billion and 2025 364-Day Revolving Facility of $1.0 billion) provide substantial liquidity and financial flexibility.

Negatives

• Net earnings and diluted EPS decreased significantly for both the three-month (7.2% and 5.7%) and nine-month (14.7% and 12.4%) periods ended September 30, 2025, primarily due to acquisition costs, higher interest expense, and a higher effective tax rate.
• Interest expense, net, increased substantially to $75.4 million for the three months and $220.9 million for the nine months, driven by higher average debt balances and interest rates related to acquisitions.
• The effective tax rate (ETR) increased to 17.2% for the three months and 22.6% for the nine months ended September 30, 2025, compared to favorable tax benefits in the prior year periods.
• Selling, general and administrative (SG&A) expenses increased as a percentage of net sales (40.5% for three months, 39.8% for nine months), due to Paragon 28 expenses, direct-to-patient marketing, IT investments, and higher performance-related compensation.
• Intangible asset amortization expense increased in amount and as a percentage of net sales due to recent acquisitions.
• Operating profit as a percentage of net sales decreased across all segments (Americas, EMEA, Asia Pacific) due to higher manufacturing costs and the lower operating profit margin of the Paragon 28 acquisition.
• Anticipate approximately $40 million of additional expenses related to tariffs for the full year 2025.
• Net cash used in investing activities significantly increased to $1,653.7 million for the nine-month period, primarily due to the Paragon 28 acquisition.

Risks

• Intense competition and pricing pressures in the medical device industry.
• Dependence on new product development, technological advances, and innovation for sustained growth.
• Challenges in attracting, retaining, developing, and maintaining highly skilled employees, senior management, and distribution networks.
• Risks and uncertainties related to the successful execution of restructuring plans and the realization of anticipated cost savings.
• Difficulty in realizing the anticipated benefits of acquisitions, including the possibility that expected synergies will not be achieved or within the expected timeframe.
• Integration risks associated with acquired businesses, including operational, product, service provider, and employee integration.
• Potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions.
• Unplanned delays, disruptions, and expenses attributable to enterprise resource planning (ERP) and other system updates.
• Dependence on a limited number of suppliers for key raw materials and components, leading to supply chain disruption risks.
• Breaches or failures of information technology systems, including cyberattacks, unauthorized access, or theft.
• The outcome of government investigations and the impact of healthcare reform and cost containment measures.
• Impact of substantial indebtedness on the ability to service debt obligations and/or refinance at maturity on favorable terms.
• Changes in tax obligations arising from examinations by tax authorities and changes in tax laws, including ongoing disputes with the IRS.
• The risk of additional tax liability due to the recategorization of independent agents and distributors to employees.
• Changes in tariffs relating to imports to the U.S. and other countries.
• Risk of material impairment of the carrying value of intangible assets, including goodwill, which could negatively affect operating results.
• Changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations, inflation, and political/social instability.
• Challenges relating to changes in and compliance with governmental laws and regulations, including FDA and EU Medical Device Regulation.
• Product liability, intellectual property, and commercial litigation losses, which could result in significant charges or affect product marketability.

Future Outlook

The company expects 2025 full year-over-year revenue growth of 6.7% to 7.7%, driven by the Paragon 28 acquisition (contributing 2.7%), market growth, and new product introductions. Foreign currency exchange rates are anticipated to have a positive impact of 0.5% to 1.0% on full-year net sales. However, net earnings are estimated to decrease in 2025 compared to 2024 due to higher acquisition and integration costs, increased operating expenses and intangible asset amortization from the Paragon 28 acquisition, higher manufacturing costs (inflation, tariffs), increased net interest expense from higher interest rates and borrowings, and a higher estimated effective tax rate. These unfavorable factors are expected to be partially offset by higher net sales, leverage from fixed operating expenses, and ongoing savings from restructuring plans.

Management Comments

• "Net sales growth was driven by a combination of our Paragon 28 acquisition, market growth, new product introductions, and lower net sales in the prior year periods due to operational challenges fulfilling customer orders as a consequence of a new enterprise resource planning ('ERP') software system implementation."
• "We expect 2025 full year-over-year revenue growth of 6.7 percent to 7.7 percent in 2025, driven by a combination of Paragon 28 net sales, market growth and new product introductions."
• "We estimate net earnings will decrease in 2025 when compared to 2024 due to higher acquisition and integration costs, operating expenses and intangible asset amortization related to the Paragon 28 acquisition, higher manufacturing costs caused by inflation, tariffs, higher net interest expense due to higher interest rates and increased borrowings and a higher estimated effective tax rate due to favorable 2024 adjustments that are not expected to recur."

Industry Context

The company operates in the global orthopedic and medical device market, which is experiencing growth driven by demographic changes and technological advancements. Strategic acquisitions like Paragon 28 (foot and ankle) and Monogram Technologies (orthopedic robotics) position the company in faster-growing segments and leverage AI-driven surgical guidance. The industry faces ongoing pricing pressure from healthcare cost containment efforts by hospitals, health systems, and governments, which the company is actively working to offset through internal initiatives and passing on inflationary impacts.

Comparison to Industry Standards

• The company's net sales growth is attributed to 'market growth' and 'new product introductions,' suggesting performance in line with or exceeding general industry expansion.
• The company notes success in 'offsetting negative effects of pricing pressure due to internal initiatives and being able to pass some inflationary impacts on to customers,' indicating effective management of a common industry challenge.
• Strategic acquisitions in areas like foot and ankle (Paragon 28) and orthopedic robotics (Monogram Technologies) align with broader industry trends towards specialized, high-growth segments and advanced surgical technologies, positioning the company competitively.

Legal Proceedings

• Involved in various legal proceedings including product liability, intellectual property, stockholder matters, tax disputes, commercial disputes, employment matters, whistleblower and qui tam claims, and governmental investigations.
• Specific product liability claims relate to the Durom Cup, Zimmer M/L Taper, M/L Taper with Kinectiv Technology, Versys Femoral Head, and the M2a-Magnum hip system.
• Accrued litigation liabilities were $146.6 million as of September 30, 2025.
• The company has succeeded to Paragon 28's existing litigation matters, with immaterial liabilities recognized.
• Under continuous audit by the IRS, with proposed adjustments for tax years 2013-2015 (transfer pricing) and 2016-2019 (U.S. taxation of foreign earnings and profits, potentially resulting in an additional $312 million tax expense plus interest). The company intends to vigorously contest these adjustments.

Stakeholder Impact

• Shareholders: Impacted by declining net earnings and EPS, but also by ongoing quarterly dividends and a share repurchase program. Strategic acquisitions aim for long-term value but introduce integration risks and immediate cost pressures. Tax and legal disputes pose potential financial liabilities.
• Employees: Affected by restructuring plans, which involve employee termination benefits, but also by investments in technology and growth opportunities.
• Customers: Benefit from new product introductions, expanded portfolios (e.g., foot and ankle, robotics), and improved service from acquisitions (e.g., EMEA distributor).
• Suppliers: The company's dependence on a limited number of suppliers for key raw materials and components creates potential supply chain risks.
• Creditors: Impacted by the increase in long-term debt and interest expense, though new credit facilities provide liquidity and the company reports compliance with debt covenants.

Next Steps

• Finalize the purchase price allocation for the Paragon 28 acquisition, expected no later than one year after the acquisition date.
• Complete the integration of Paragon 28, including enhancing its internal controls to align with the company's framework.
• Integrate the recently acquired Monogram Technologies Inc. and work towards achieving its product development, regulatory, and revenue milestones through 2030.
• Continue to realize gross annual pre-tax operating expense reductions of approximately $95 million from the 2025 Restructuring Plan by the end of 2027.
• Realize gross annual pre-tax operating expense reductions of $175 million to $200 million from the 2023 Restructuring Plan by the end of 2025.
• Complete the closure of a manufacturing facility in the fourth quarter of 2025 to fully realize the benefits of the 2019 Restructuring Plan.
• Vigorously contest proposed IRS adjustments for tax years 2013-2015 and 2016-2019, pursuing all available administrative and judicial remedies.
• Continue paying quarterly cash dividends, subject to Board approval.
• Potentially execute further share repurchases under the remaining $1,020.2 million authorization.

Key Dates

Recommendation

The company presents a mixed financial picture with strong top-line sales growth driven by strategic acquisitions in high-growth areas like foot and ankle and orthopedic robotics. This indicates a proactive approach to market expansion and innovation. However, this growth comes at a significant cost, as evidenced by the decline in net earnings and diluted EPS, increased interest expense from higher debt, and a higher effective tax rate. While restructuring efforts are expected to yield future savings, the immediate impact on profitability is negative. Furthermore, ongoing and material legal and tax disputes with the IRS introduce considerable uncertainty regarding future financial outcomes. For a seasoned investor, a 'Hold' recommendation is appropriate to allow time for the integration of recent acquisitions to mature, for the full benefits of restructuring plans to materialize, and for clarity on the resolution of significant legal and tax contingencies. The long-term strategic positioning is promising, but current financial headwinds and uncertainties warrant a cautious stance.

Keywords

Zimmer Biomet, ZBH, Orthopedics, Medical Devices, Q3 2025, Earnings Report, Net Sales, Net Earnings, Acquisitions, Paragon 28, Monogram Technologies, Robotics, Restructuring, Debt Issuance, SEC Filing, 10-Q